RedHill Biopharma (RDHL) FCF Margin (2012 - 2023)
RedHill Biopharma's (RDHL) quarterly FCF Margin came in at 589.59% in Q2 2023, down 50010.0% year-over-year from N/an in Q2 2022, and down 195.29% quarter-over-quarter from 199.67% in Q1 2023.
Powered by 
Analysis
RedHill Biopharma (RDHL) FCF Margin (2012 - 2023) Analysis & Trends
RedHill Biopharma (RDHL) has reported FCF Margin for 12 consecutive years, with 589.59% the latest figure, recorded in Q2 2023.
- On a quarterly basis, FCF Margin fell 50010.0% year-over-year to 589.59% in Q2 2023; TTM through Jun 2023 was 73.3%, a 87.0% decrease from a year earlier, with the FY2025 full-year figure at 3372.73%, down 325635.0% from the prior year.
- FCF Margin was 589.59% for Q2 2023 at RedHill Biopharma, down from 199.67% in the prior quarter.
- Over five years, FCF Margin peaked at 18.92% in Q4 2022 and troughed at 983.14% in Q1 2020.
- A 5-year average of 278.98% and a median of 87.91% in 2021 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin tumbled 54981 bps in 2020 and surged 92395 bps in 2021, its largest moves.
- Over 5 years, FCF Margin stood at 870.19% in 2019, then surged by 93 bps to 58.97% in 2020, then fell by 14 bps to 67.31% in 2021, then jumped by 72 bps to 18.92% in 2022, then tumbled by 3017 bps to 589.59% in 2023.
- The last three FCF Margin figures came in at 589.59% (Q2 2023), 199.67% (Q1 2023), and 18.92% (Q4 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.33 Bn | 38.68 Bn | 2.15 Bn | 7.41% |
| 2 | Viatris | 19.05 Bn | 18.16 Bn | 1.46 Bn | 8.76% |
| 3 | Dr Reddys Laboratories | 9.76 Bn | 9.58 Bn | 396.53 Mn | 3.10% |
| 4 | Amneal Pharmaceuticals | 5.38 Bn | 5.25 Bn | 334.51 Mn | -6.52% |
| 5 | Bausch Health Companies | 2.27 Bn | 436.38 Mn | 2.10 Bn | 20.79% |
| 6 | Alvotech | 1.51 Bn | 1.37 Bn | 2.56 Mn | 14.76% |
| 7 | Ani Pharmaceuticals | 1.51 Bn | 1.15 Bn | 165.89 Mn | 20.15% |
| 8 | Amphastar Pharmaceuticals | 1.03 Bn | 737.26 Mn | 93.47 Mn | 23.24% |
| 9 | Fennec Pharmaceuticals | 393.12 Mn | 351.87 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 171.02 Mn | 171.02 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -589.59% |
| Mar 31, 2023 | -199.67% |
| Dec 31, 2022 | -18.92% |
| Sep 30, 2022 | -34.22% |
| Jun 30, 2022 | -89.49% |
| Mar 31, 2022 | -31.61% |
| Dec 31, 2021 | -67.31% |
| Sep 30, 2021 | -87.94% |
| Jun 30, 2021 | -87.88% |
| Mar 31, 2021 | -59.19% |
| Dec 31, 2020 | -58.97% |
| Sep 30, 2020 | -43.00% |
| Jun 30, 2020 | -71.82% |
| Mar 31, 2020 | -983.14% |
| Dec 31, 2019 | -870.19% |
| Sep 30, 2019 | -634.76% |
| Jun 30, 2019 | -660.59% |
| Mar 31, 2019 | -433.33% |
| Dec 31, 2018 | -602.58% |
| Sep 30, 2018 | -379.37% |